NAD+ has become one of the most buzzed-about molecules in longevity science, fueling both a surge of research and a booming market. But beneath the hype, key questions about its real-world impact remain unsettled. That debate is taking center stage this week at the “NAD for Health: Opportunities and Challenges” conference (March 23–25), where leading researchers are convening to scrutinize the evidence, challenge prevailing assumptions, and confront the field’s biggest unknowns.

Mathias Ziegler, MD, PhD, one of the world’s foremost experts on NAD biology, professor of biomedicine at the University of Bergen in Norway and chief science officer of Blue Helix Health, will present on the critical role of mitochondria in maintaining NAD balance — one of the most fundamental questions in aging biology. 

“We need to make more than our body’s weight in NAD every day,” said Ziegler. “Why? Because there are so many processes driven by this molecule. We are trying to use this knowledge to actually help people live better.” 

New Jersey-based NXT USA is the exclusive distributor of Blue Helix technologies, including its flagship BluNADBooster ingredient, connecting this next wave of NAD science directly to supplement brands seeking real differentiation.

The NAD+ Conversation

At the Copenhagen NAD conference, Ziegler also serves as a moderator for a panel discussion tackling the translational reality of NAD+ therapeutics. 

This is not a conference built on consensus but on investigation. Sessions openly question:

• Key knowledge gaps and heated controversies
• The real-world outcomes of human trials
• The biological limits of current precursor technologies 

With decades of research into NAD biology, including enzymatic pathways, compartmentalization (whether increased NAD levels translate to functional outcomes), and mitochondrial function, Ziegler’s work helps bridge the gap between mechanistic science and practical application. 

While much of the NAD+ conversation remains theoretical or debated, Blue Helix Health is focused on translating emerging science into real-world solutions. BluNADBooster is designed to elevate and sustain NAD+ levels, addressing a core limitation seen in first-generation NAD precursor approaches, according to the company.

BluNADBooster was evaluated in a randomized, double-blind, placebo-controlled clinical trial published in December 2025 involving 140 healthy aging adults, where it demonstrated a multi-pathway impact on NAD+ biology — raising NAD+ levels by 26.48% while also reducing CD38 activity by nearly 18%, a key driver of age-related NAD+ decline. 

“The market has been waiting for an NAD+ solution that goes beyond precursors alone,” said Eric Anderson, managing director at NXT USA. “BluNADBooster represents a next-generation approach — one that strengthens the body’s ability to generate and maintain healthy NAD+ levels while addressing the underlying mechanisms that cause NAD+ to decline with age.” 

For formulators, brands, and ingredient buyers, NAD+ is an evolving story of mechanisms, efficacy claims, and clinical validation.

Blue Helix Health, through its scientific leadership and technologies like BluNADBooster, as well as its exclusive partnership with NXT USA, is positioning itself at that intersection where rigorous biology meets commercial innovation.

“We’re working on things like laboratory analysis of NAD, clinical research, and ways to supplement with NAD-boosting strategies,” said A. Suthar, PhD, managing director of Blue Helix Health. “We’re excited to hear from some of the leading researchers in the field in Copenhagen.”